ZLAB Zai Lab
- 17.780
- -0.410-2.25%
- 17.780
- 0.0000.00%
Zai Lab News
Institutional Owners May Take Dramatic Actions as Zai Lab Limited's (NASDAQ:ZLAB) Recent 4.4% Drop Adds to One-year Losses
Key Insights Institutions' substantial holdings in Zai Lab implies that they have significant influence over the company's share price 51% of the business is held by the top 9 shareholders Ownersh
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 1.01% to 1,951.87 on the S&P Asia 50 ADR Index. Despite the gain, the index is set to close
Zai Lab Doses First Subject in Phase II Plaque Psoriasis Treatment Trial
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai's global capabilities Based on a proof-of-concept study, ZL-1102 is the first topical biologic to
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zaiding Pharmaceutical (09688.HK): China Drug Administration approved Dingyule (sulbactam sodium-dulobactan sodium) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Ba
Zaiding Pharmaceutical (09688.HK) announced that China's State Drug Administration has approved a new drug marketing application for Dingyule (sulbactan sodium-dulobactan sodium) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Baumann-Calcium Acetate Acinetobacter complex in patients aged 18 and above.
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter B
Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
Zaiding Pharmaceutical granted a total of 50,400 share options and 37,400 restricted share units
Zaiding Pharmaceutical (09688) announced that on May 14, 2024 (US Eastern Time), the company granted 3 grantees the right to subscribe for a total of 50,400 American Depositary Shares and granted restricted share units involving a total of 37,400 American Depositary Shares to 6 grantees in accordance with the 2022 Equity Incentive Plan. The exercise price of the share options granted was $21.55 per American Depositary Share.
Zai Lab(ZLAB.US) Officer Sells US$213.35K in Common Stock
$Zai Lab(ZLAB.US)$ Officer Edmondson Frazor Titus III sold 10,000 shares of common stock on May 14, 2024 at an average price of $21.3346 for a total value of $213.35K.Source: Announcement What is stat
Zaiding Pharmaceutical (09688.HK) received 19.513 million shares from J.P. Morgan
Glonghui, May 16 | According to the latest equity disclosure data on the Stock Exchange, on May 10, 2024, Zaiding Pharmaceutical (09688.HK) obtained JPMorgan Chase & Co. increased its holdings by 19.513 million shares at an average price of HK$15.9063 per share, involving approximately HK$310 million. After the increase in holdings, JPMorgan Chase & Co.'s latest number of open positions was 175,310,714 shares, and the holding ratio increased from 15.70% to 17.67%.
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
Asian equities traded in the US as American depositary receipts eased Thursday morning, declining 0.04% to 1,950.23 on the S&P Asia 50 ADR Index and paring earlier losses. From North Asia, the gainers
Zaiding Pharmaceutical (09688) granted a total of 50,400 share options and 37,400 restricted share units
Zaiding Pharmaceutical (09688) issued an announcement. On May 14, 2024 (EST), the company based on 2...
Zai Lab Announces Participation in May and June Investor Conferences
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in May and June 2024: J.P. Morgan 20th Annual
Zai Lab(ZLAB.US) Officer Buys US$64,200 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Smiley Joshua L purchased 3,000 shares of common stock on May 13, 2024 at an average price of $21.4 for a total value of $64,200.Source: Announcement What is statement of ch
Analysts Are Bullish on These Healthcare Stocks: Zai Lab (ZLAB), Alphatec Holdings (ATEC)
Analyst Upgrades Zai Lab's Price Objective on Strong Drug Portfolio and Growth Prospects
Form 144 | Zai Lab(ZLAB.US) Officer Proposes to Sell 213.35K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $ZAI LAB LIMITED(ZAILF.US)$、$Zai Lab(ZLAB.US)$ Officer Edmondson Frazor Titus III intends to sell 10,000 shares of its common stock on May 14, with a total market value
Analysis
Price Target
No Data
